Evidence map›Paper›PMID 28931091›Full record

ArticlePLoS pathogens2017

T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy.

Allison S Thomas, Kimberley L Jones, Rajesh T Gandhi, Deborah K McMahon, Joshua C Cyktor, Dora Chan, Szu-Han Huang, Ronald Truong, Alberto Bosque, Amanda B Macedo and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 54 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. HIV Nef amplifies mechanical heterogeneity to promote immune evasion.bioRxiv : the preprint server for biology · 2025
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 2 countries.

Allison S ThomasDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.
Kimberley L JonesDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0001-9136-0877
Rajesh T GandhiRagon Institute of MIT, MGH, and Harvard, Cambridge MA, United States of America.
Deborah K McMahonDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
Joshua C CyktorDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.ORCID http://orcid.org/0000-0003-3601-4837
Dora ChanDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0002-7777-3293
Szu-Han HuangDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0003-1420-3186
Ronald TruongDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.
Alberto BosqueDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0002-8800-2160
Amanda B MacedoDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.
Colin KovacsMaple Leaf Medical Clinic, Toronto, Canada.
Erika BenkoDivision of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.
Joseph J EronDivision of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States of America.ORCID http://orcid.org/0000-0002-4938-0644
Ronald J BoschHarvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.
Christina M LalamaHarvard TH Chan School of Public Health, Boston, Massachusetts, United States of America.ORCID http://orcid.org/0000-0001-6711-481X
Samuel SimmensDepartment of Epidemiology and Biostatistics, George Washington University, Milken Institute School of Public Health, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0001-7830-8003
Bruce D WalkerRagon Institute of MIT, MGH, and Harvard, Cambridge MA, United States of America.ORCID http://orcid.org/0000-0001-6122-9245
John W MellorsDivision of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, United States of America.
R Brad JonesDepartment of Microbiology Immunology and Tropical Medicine, George Washington University, Washington, District of Columbia, United States of America.ORCID http://orcid.org/0000-0003-4470-1231
George Washington University · USUniversity of Pittsburgh · USHarvard University · USUniversity of North Carolina at Chapel Hill · USHoward Hughes Medical Institute · USMaple Leaf Medical Clinic · CAMilken Institute · USRagon Institute of MGH, MIT and Harvard · US

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
Validation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8M
Disparities in COVID Disease Severity and Outcomes in New York CityUL1TR002384 · NCATS · WEILL MEDICAL COLL OF CORNELL UNIV · PI JULIANNE L IMPERATO-MCGINLEY · 2017 to 2026
$86.2M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
University of Pittsburgh Clinical Trials UnitUM1AI069494 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SUSAN L KOLETAR, John W Mellors · 2012 to 2026
$38.0M
SWG 2: Cure Research Scientific Working GroupP30AI117970 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Italo Mocchetti · 2015 to 2026
$29.6M
BELIEVE: Bench to Bed Enhanced Lymphocyte Infusions to Engineer Viral EradicationUM1AI126617 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD, NIXON, DOUGLAS F · 2016 to 2020
$28.1M
University of Puerto Rico Clinical Trials UnitUM1AI069415 · NIAID · UNIVERSITY OF PUERTO RICO MED SCIENCES · PI FEBO, IRMA LUZ, SANTANA-BAGUR, JORGE L. · 2012 to 2021
$15.2M
CTL-Mediated Elimination of Replication Competent vs. Defective HIV Proviruses from Natural Latent Reservoirs: Roles of Antigen Specificity and Functional CharacteristicsR01AI131798 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2017 to 2021
$2.1M
NCATS NIH HHS UL1 TR002384NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI117970NIAID NIH HHS R01 AI131798NIAID NIH HHS U01 AI068634NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069494NIAID NIH HHS UM1 AI106701NIAID NIH HHS UM1 AI126617NIH HHS S10 OD021622
6 · The paper itself

Abstract

HIV-specific CD8+ T-cell responses limit viral replication in untreated infection. After the initiation of antiretroviral therapy (ART), these responses decay and the infected cell population that remains is commonly considered to be invisible to T-cells. We hypothesized that HIV antigen recognition may persist in ART-treated individuals due to low-level or episodic protein expression. We posited that if persistent recognition were occurring it would be preferentially directed against the early HIV gene products Nef, Tat, and Rev as compared to late gene products, such as Gag, Pol, and Env, which have higher barriers to expression. Using a primary cell model of latency, we observed that a Nef-specific CD8+ T-cell clone exhibited low-level recognition of infected cells prior to reactivation and robust recognition shortly thereafter. A Gag-specific CD8+ T-cell clone failed to recognized infected cells under these conditions, corresponding with a lack of detectable Gag expression. We measured HIV-specific T-cell responses in 96 individuals who had been suppressed on ART for a median of 7 years, and observed a significant, direct correlation between cell-associated HIV DNA levels and magnitudes of IFN-γ-producing Nef/Tat/Rev-specific T-cell responses. This correlation was confirmed in an independent cohort (n = 18). Correlations were not detected between measures of HIV persistence and T-cell responses to other HIV antigens. The correlation with Nef/Tat/Rev-specific T-cells was attributable to Nef-specific responses, the breadth of which also correlated with HIV DNA levels. These results suggest that ongoing Nef expression in ART-treated individuals drives preferential maintenance and/or expansion of T-cells reactive to this protein, implying sensing of infected cells by the immune system. The direct correlation, however, suggests that recognition does not result in efficient elimination of infected cells. These results raise the possibility that enhancing the cytolytic activity of Nef-specific T-cells may lead to reductions in infected cell frequencies, even in the absence of therapeutic latency reversal.

Indexed as

Anti-Retroviral AgentsCD8-Positive T-LymphocytesEnzyme-Linked Immunospot AssayHIV InfectionsHumansnef Gene Products, Human Immunodeficiency VirusPolymerase Chain ReactionVirus LatencyAnti-Retroviral Agentsnef Gene Products, Human Immunodeficiency Virus

Identifiers

PMID28931091
PMCPMC5624641
OpenAlexW2755939206

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.